Professional Documents
Culture Documents
EXAMINE LESS
40-65 years
Malignant neoplasms Cardio-Vascular Disease Pulmonary Disease
N501 Wendy Smith
40 to 65 Age Group
Contributing Causes
Maligant Neoplasms: smoking/tobacco use, diet/nutrition, exposure to toxic/noxious agents, genetics Cardio-Vascular Disease: smoking/tobacco use, diet/nutrition/hyperlipidemia, genetics Pulmonary Disease: smoking, exposure to toxic/noxious agents
N501 Wendy Smith
Weight
not nec q visit unless other risk factors establish a baseline observe for fluctuations, BMI each decade. Wt (kg)/Ht (m sq).
N501 Wendy Smith
Controversy
Some major studies questioned if mammography screening reduces mortality in women younger than 50 yrs -- Morbidity!!
N501 Wendy Smith
Women 65 yrs +
USPSTF & CTFPHE screen as above until 70, Again controversy, Am Geri Society recommends >65 q 2-3 yrs until 85 yr.
N501 Wendy Smith
USPSTF routine screening by PSA, DRE or Utrasound not recommended ACS, A Uro Assoc, Annual test > 50 yr
N501 Wendy Smith
Offer STD screening, even if asymptomatic, if hx is reveals risk factors. In all age groups! N501 Wendy Smith
Immunizations
Tetanus-Diptheria (Td) q 10 yr,
ACP single booster at 50 yrs if received initial series
Immunizations
Pneumoccocal
CTFPHE all persons 55 yr or > USPSTF all persons 65 yr or >, or if younger and have any of the following risks
Cardiac, Pulmonary, Renal disease, DM, Sickle Cell Disease, post chemo, living conditions that place at risk ie. Poverty, homelessness etc.
USPSTF revaccinate in high risk folks who were vaccinated > 5 yrs previous
N501 Wendy Smith
Immunization
Influenza, offer annually to all individuals 65 yrs of age or older. Also offer to adults who are at increased risk for influenza related complications
Chronic Pulmonary and Cardiac disorders or those who may transmit influenza to individuals at risk i.e. health care worker and household members of immunocompromised
N501 Wendy Smith
Other
PPD skin test with Mantoux all individuals at high risk.
Close contact with persons known or suspected to have TB, HIV+, inject illicit drugs or other high risk substance abusers (crack cocaine), immunocompromised, residents and employees of high-risk congregate setting (correctional, nursing home, mental institutions, homeless/residential facilities, health care workers, immigrants/refugees
N501 Wendy Smith
Pharmaceuticals
ASA
AAFP men aged 40 to 84 yrs with risk factors for CAD informed of the risk/benefit of prophylaxis CTFPHE does not support routine ASA therapy for primary prevention in asymptomatic men or women USPSTF insufficient evidence for or against use for primary prevention in asymptomatic
N501 Wendy Smith
Pharmaceuticals
Estrogen, Progestin (HRT)
AAFP all perimenopausal women should be counseled about the benefits and risks of postmenopausal HRT ACOG, ACP, USPSTF, CTFPHE All peri and post Meno women should be counseled regarding the probable risks and benefits of HRT so they can make informed choice
N501 Wendy Smith
Pharmaceuticals
HRT
USPSTF insuff evidence +/- to recommend HRT in all women as primary prevention. ACP All women
regardless of race should consider preventive hormone therapy Hysterectomized women no need to add Progestin Women with CAD, or at increased risk benefit Consider risk/benefit in those at increased risk for Breast Cancer
N501 Wendy Smith
Pharmaceuticals
HRT Secondary prevention or relief of symptoms
Unless contraindicated offer to all for secondary prevention or relief of climacteric symptoms. Advise of risk/benefit
contradindications complete and relative: smoker, family or personal hx of breast cancer, hx of migraines, hx of thromboembolic disease, Liver disease, hx of reproductive cancer: ovary, uterus, gallbladder disease, familial hyperlipidemia, fibroids, endometriosis, seizure disorder, hypertension, unexplained vag bleeding
N501 Wendy Smith